About Us

About Advanced Biological Laboratories (ABL SA)
Improving Disease Management

Advanced Biological Laboratories (ABL), S.A., is a diagnostic and medical software company founded in 2000 as a spin-off from CRP-Santé (https://www.lih.lu/) Luxembourg.
ABL's products offer to infectious disease clinicians, virology and microbiology laboratories
- Assays and standalone software systems for accredited laboratories (i.e. ISO 15189), mainly for microbiology applications (related to HIV, Coronavirus, Tuberculosis, HCV, HBV, HPV, CMV, HPV, Flu, 16s RNA…) for clinical genotyping through sequencing (DeepChek®), DNA and RNA detection and quantification (UltraGene®), including powerful downstream analysis software applications fully integrated with knowledge databases and analysis systems for capillary and high-throughput Next Generation Sequencing data.
- Clinical software applications for infectious diseases units
- IT dashboards and clinical database aggregation applications for research and clinical management
ABL took in 2013 the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL as well as a personalized medicine electronic medical record system (EMR) in infectious disease from GlaxoSmithKline in 2016. In July 2018, acquired CDL Pharma to develop CRO related services and assays manufacturing capacity. In June 2019, ABL created its affiliate in the USA (AdvancedDx Biological Laboratories) covering the entire North American territory.

ABL has a comprehensive suite of healthcare management products, including Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, UltraGene®, VisibleChek®, HepatiC®, BacterioChek, MicrobioChek and the DPM used for data and patient management, monitoring and personalized reporting applications. Since 2012, some of ABL's products are CE-IVD marked. In 2020, ABL got CE-IVD marking for its DeepChek®-HIV assays as well as for its UltraGene Combo2ScreenSARS-CoV-2 assay. The other products are currently available for Research Use Only.


Press releases

Advanced Biological Laboratories (ABL) Releases the First & Unique...

Advanced Biological Laboratories (ABL) announced today the CE-IVD marking of its UltraGene® Combo2Screen SARS-CoV-2 qPCR assay. It is the first... read more

06.07.2020 • By Advanced Biological Laboratories

SARS-CoV-2 PCR Assay Now Approved for Human Saliva Specimens

Advanced Biological Laboratories (ABL) announced today the validation of its CE-IVD UltraGene® Combo2Screen SARS-CoV-2 qPCR assay to be used... read more

17.06.2020 • By Advanced Biological Laboratories

Advanced Biological Laboratories Receives CE-IVD Registration for its...

Luxembourg (Luxembourg), Metz (France) — May 21 — Advanced Biological Laboratories (ABL) announced today the CE-IVD registration of its... read more

21.05.2020 • By Advanced Biological Laboratories

Contact